Mumbai, India - Genomate Health, leading provider of AI-powered precision oncology solutions, proudly announces its presence at the 3rd Indian Cancer Congress (ICC) 2023. This prestigious event, held from November 2nd to 5th at the Jio World Convention Centre in Mumbai, brought together a multitude of oncology stakeholders from India and around the world.

The Indian Cancer Congress serves as a vital platform that unites oncologists, scientists, allied specialists, advocacy groups, and policymakers engaged in cancer care in India. It is a collaborative effort between India's four largest professional oncology societies: the Indian Association of Surgical Oncology (IASO), the Indian Society of Oncology (ISO), the Indian Society of Medical and Paediatric Oncology (ISMPO), and the Association of Radiation Oncologists of India (AROI). With the theme "Continuum of Care in Cancer," the 3rd ICC attracted approximately 6,000 oncology professionals from India, neighboring countries, the Middle East, Southeast Asia, Europe, Africa, and North America. The conference facilitated discussions on cutting-edge cancer treatments, research, and patient care practices, offering a platform to exchange knowledge and expertise.

Genomate Health's participation at the ICC was made possible through its local partner, Intelligene Healthcare Pvt Ltd. Together, they showcased Genomate's innovative AI-powered solutions for precision oncology: the world’s first computational reasoning system that can predict response to thousands of targeted therapies based on millions of possible combinations of genetic biomarkers.

Istvan Petak, CEO and Founder of Genomate Health, expressed his enthusiasm about the company's presence at the event, stating, "The Indian Cancer Congress is an invaluable opportunity for us to connect with the oncology community in India and beyond. Genomate Health is dedicated to transforming cancer care through AI-driven precision oncology, and we are excited to contribute to the discourse on improving cancer treatment outcomes."

Genomate Health expresses its gratitude to the ICC 2023 organizing committee for hosting this influential event and to all participants who visited their booth. As Genomate Health continues to drive innovation in cancer care, it remains committed to collaborating with healthcare professionals and organizations worldwide to make a lasting impact on the lives of cancer patients.

For more information about Genomate Health and its pioneering work in precision oncology, please visit www.genomate.health.

‍

About Genomate Health

Genomate Health Inc. is a digital health company (based in Cambridge, MA) that develops AI-powered computational tools for personalized medicine. Its main focus is assisting physicians in making optimal personalized treatment decisions for each patient based on the complex molecular characteristics of human diseases.

Its flagship product, Genomate® MTC (Molecular Treatment Calculator), is a powerful computational (open box AI) tool aiming to optimize treatment decision-making in precision oncology by automated data compilation, evaluation, and synthesis in a knowledge model allowing standardized, personalized treatment decisions based on the totality of available molecular information. The company’s goal is to make this solution globally available to cancer patients and their oncologists in 2023. For more information, visit www.genomate.health, and follow the momentum on Facebook, Twitter, Instagram, and LinkedIn.

‍

Media Inquiries:

Alina Luchian

Brand Manager, Genomate Health Inc

alina.luchian(at)genomate.health